证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-139 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）及子公司福建盛迪 医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关 于 HRS-4729 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 现将相关情况公告如下： 药物名称：HRS-4729 注射液 剂 型：注射剂 申请事项：临床试验 受 理 号：CXHL2500558、CXHL2500559 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 6 月 11 日受理的 HRS-4729 注射液临床试验申请符合药品注册的有关要求，同 意本品开展临床试验，申请的适应症为代谢相关脂肪性肝病/代谢相关脂肪性肝 炎。 二、药物的其他情况 HRS-4729 注射液是公司自主研发的多肽类药物，是一种胰高血糖素样肽-1 受体（GLP-1R）/葡萄糖依赖性 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances metabolic regulation compared to dual-target therapies [1] - The drug promotes energy expenditure, fatty acid oxidation, and lipid breakdown, leading to better weight loss and reduction of liver fat [1]

MACD金叉信号形成，这些股涨势不错！ 格隆汇9月4日丨恒瑞医药(600276.SH)公布，2025年9月4日，公司通过集中竞价交易方式首次回购A股股 份270,000股，已回购股份占公司总股本的比例为0.004%，成交的最高价为67.97元/股，最低价为67.75 元/股，已支付的总金额为18,313,920元（不含交易费用）。上述回购符合相关法律法规的规定及公司既 定的回购股份方案。 ...

Group 1 - The core point of the article is that Heng Rui Medicine (600276.SH) announced that its subsidiary, Ruishi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of RSS0393 ointment [1] - RSS0393 ointment is a self-developed product by the company, which contains a PDE4 small molecule inhibitor that can alleviate tissue damage and inflammation by inhibiting PDE4 activity in various cells [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of its self-developed peptide drug HRS-4729 injection, which is expected to commence soon [1] Group 1: Product Development - HRS-4729 injection is a multi-peptide drug that acts as a triple agonist for GLP-1R, GIPR, and GCGR receptors [1] - The triple receptor activation enhances the regulation of glucose and lipid metabolism, appetite suppression, and promotes energy expenditure, fatty acid oxidation, and lipid breakdown, leading to better weight loss and reduction of liver fat compared to dual-target GLP-1R/GIPR [1]

智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司瑞石生物医药有限公司收到国家 药品监督管理局(简称"国家药监局")核准签发关于RSS0393软膏的《药物临床试验批准通知书》，将于 近期开展临床试验。 SS0393软膏是公司自主研发的含PDE4小分子抑制剂的软膏，涂抹后可通过抑制多种细胞内的PDE4活 性，缓解组织损伤和炎症。 ...

Core Viewpoint - The company received approval from the National Medical Products Administration for the clinical trial of HRS-4729 injection, a self-developed peptide drug targeting multiple receptors for better weight loss and liver fat reduction [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances energy expenditure and lipid metabolism [1] - The drug aims to improve weight loss and reduce liver fat more effectively compared to dual-target GLP-1R/GIPR agonists [1] Group 2: Clinical Trial - The clinical trial for HRS-4729 injection will commence shortly following the approval [1]

恒瑞医药9月4日公告，子公司瑞石生物医药有限公司收到国家药监局核准签发关于RSS0393软膏的《药 物临床试验批准通知书》，将于近期开展临床试验。RSS0393软膏是公司自主研发的含PDE4小分子抑 制剂的软膏，涂抹后可通过抑制多种细胞内的PDE4活性，缓解组织损伤和炎症。 ...

Group 1 - The company announced a share repurchase of 270,000 A-shares, representing 0.004% of its total share capital [1] - The repurchase price ranged from 67.75 yuan to 67.97 yuan per share, with a total expenditure of 18.31 million yuan [1] - The purpose of the repurchase is to implement an employee stock ownership plan, with a maximum repurchase price set at 90.85 yuan per share and an expected total amount between 1 billion to 2 billion yuan [1]

来源：滚动播报 香港恒生指数收跌1.12%，恒生科技指数跌1.85%。芯片股普跌，中芯国际、上海复旦跌超6%，华虹半 导体跌超5%；创新药概念股回调，歌礼制药跌超10%，恒瑞医药跌超6%；黄金板块下跌，灵宝黄金、 中国黄金国际跌超7%。 ...